Current and future treatments of osteoporosis in men.
Abstract One in three osteoporotic fractures occur in men and the consequences of a fracture in men tend to be more severe than in women. Still, only a small minority of men with high risk of fracture are detected and treated. Although there are gender differences in the pathophysiology of osteoporosis, such as in the pattern of bone loss, similarities predominate, which is also the case for clinical risk factors. It seems appropriate to consider treatment for men and women with a similar 10 year fracture risk. Drugs now approved for treatment of osteoporosis in men include the anti-resorptive bisphosphonates alen...
Source: Clinical Prostate Cancer - December 1, 2014 Category: Cancer & Oncology Authors: Kaufman JM, Lapauw B, Goemaere S Tags: Best Pract Res Clin Endocrinol Metab Source Type: research

The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON‐Pivotal Fracture Trial (PFT)
This article is protected by copyright. All rights reserved (Source: Journal of Bone and Mineral Research)
Source: Journal of Bone and Mineral Research - December 1, 2014 Category: Orthopaedics Authors: Dennis M Black, Ian R Reid, Jane A Cauley, Felicia Cosman, Ping Chung Leung, Peter Lakatos, Kurt Lippuner, Steven R Cummings, Trisha F Hue, Amitava Mukhopadhyay, Monique Tan, R Paul Aftring, Richard Eastell Tags: Clinical Trial Source Type: research

Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.
In conclusion, our results demonstrate that the encapsulation of ZOL increases the antitumor efficacy of this drug in glioblastoma through the acquisition of ability to cross the BBB. PMID: 25431953 [PubMed - in process] (Source: Oncotarget)
Source: Oncotarget - November 30, 2014 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Docetaxel with or without zoledronic acid for castration-resistant prostate cancer
Abstract Purpose The aim of this study was to evaluate the efficacy and safety of zoledronic acid (ZA) in the combination of docetaxel-based chemotherapy for castration-resistant prostate cancer with bone metastases. Methods We conducted a prospective study in recruiting 105 prostate cancer patients with bone metastases from 2008 to 2010. Patients were randomly divided into two groups, 53 in the docetaxel-based chemotherapy + ZA(Group A) and 52 in the docetaxel-based chemotherapy + placebo(Group B). The different outcome betwee...
Source: International Urology and Nephrology - November 29, 2014 Category: Urology & Nephrology Source Type: research

Additive effect of zoledronic acid and alfacalcidol in the treatment of disuse osteoporosis in rats
Conclusions These data suggest that combination therapy with ZOL plus ALF represents a potentially useful therapeutic option for the treatment of disuse osteoporosis. (Source: Revista Brasileira de Reumatologia)
Source: Revista Brasileira de Reumatologia - November 28, 2014 Category: Rheumatology Source Type: research

Effect of combined treatment with zoledronic acid and propranolol on mechanical strength in an rat model of disuse osteoporosis
Conclusions These data suggest that this combined treatment with ZOL plus PRO should be recommended for the treatment of disuse osteoporosis. (Source: Revista Brasileira de Reumatologia)
Source: Revista Brasileira de Reumatologia - November 28, 2014 Category: Rheumatology Source Type: research

The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
CONCLUSIONS: The combination of CS plus metronomic ZOL demonstrated potent anti-tumor, anti-metastasis and anti-osteolysis effects against breast cancer, suggesting the potential clinical application against breast cancer patients. PMID: 25431338 [PubMed - as supplied by publisher] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 28, 2014 Category: Cancer & Oncology Authors: Luo KW, Ko CH, Yue GG, Gao S, Lee JK, Li G, Fung KP, Leung PC, Evdokiou A, Lau CB Tags: J Cancer Res Clin Oncol Source Type: research

Effects of zoledronate on the radiation-induced collagen breakdown: a prospective randomized clinical trial
Conclusion The results indicate the ability of zoledronate to prevent the early radiation-induced bone collagen degradation suggesting that the radiation-induced bone loss is mainly caused by osteoclastic bone resorption rather than by a direct radiation-induced damage. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - November 25, 2014 Category: Cancer & Oncology Source Type: research

The effect of zoledronic acid on the volume of the fusion-mass in lumbar spinal fusion.
CONCLUSIONS: A single dose of zoledronic acid does not decrease the volume of the fusion-mass in patients undergoing spinal fusion with osteoporosis. Therefore, we recommend that zoledronic acid may be used after spinal fusion in osteoporotic patients. PMID: 24340149 [PubMed - indexed for MEDLINE] (Source: Clinics in Orthopedic Surgery)
Source: Clinics in Orthopedic Surgery - November 25, 2014 Category: Orthopaedics Tags: Clin Orthop Surg Source Type: research

Spontaneous acetabular periprosthetic fracture in a patient continuously having zoledronic acid.
Authors: Tantavisut S, Tanavalee A, Thanakit V, Ngarmukos S, Wilairatana V, Wangroongsub Y Abstract Zoledronic acid has been used for prevention of osteolytic and osteoblastic bone metastasis. This case report illustrates an undesirable consequence from prolonged usage of zoledronic acid in bone metastasis prevention. Periprosthetic acetabular fracture in a patient treated with zoledronic acid for 7 years was reported. The clinical presentation, radiographic and pathological results were described. This is a rare complication after total hip arthroplasty which should not be ignored especially in patients who receiv...
Source: Clinics in Orthopedic Surgery - November 25, 2014 Category: Orthopaedics Tags: Clin Orthop Surg Source Type: research

Effects of zoledronic acid and the association between its efficacy and ¿¿T cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol
This study evaluates the effects of zoledronic acid on the tumor response in postmenopausal women with breast cancer and explores the relationship between its efficacy and ?? T cells.Methods/designThis study is an open-label, multi-institutional, single-arm, phase II clinical trial. Zoledronic acid will be administered once during preoperative hormonal therapy with letrozole for 24?weeks in postmenopausal women with Estrogen Receptor (ER)-positive , Human Epidermal Growth Factor Receptor 2 (HER2)-negative, clinical T1 or T2 N0M0 breast cancer. The primary endpoint is the objective response rate measured by MRI at 12 and 24...
Source: Journal of Translational Medicine - November 25, 2014 Category: Research Authors: Eriko SumiTomoharu SugieKenichi YoshimuraHarue TadaTakafumi IkedaEiji SuzukiYoshimasa TanakaSatoshi TeramukaiAkira ShimizuMasakazu ToiNagahiro Minato Source Type: research

Myelosuppressive therapies significantly increase pro‐inflammatory cytokines and directly cause bone loss
This article is protected by copyright. All rights reserved (Source: Journal of Bone and Mineral Research)
Source: Journal of Bone and Mineral Research - November 22, 2014 Category: Orthopaedics Authors: Julie M. Quach, Maria Askmyr, Tanja Jovic, Emma K. Baker, Nicole C. Walsh, Simon J. Harrison, Paul Neeson, David Ritchie, Peter R. Ebeling, Louise E. Purton Tags: Original Article Source Type: research

Lipopolysaccharide aggravates bisphosphonate-induced osteonecrosis in rats
The pathogenesis of bisphosphonate-related osteonecrosis of the jaw (BRONJ) is highly controversial. We have previously reported the development of osteonecrosis by periodontal pathogenic stimulation in the jaw and femur of rats treated with bisphosphonate. Since the major toxicity factor of Gram-negative bacteria is lipopolysaccharide (LPS), the present study aimed to evaluate the relationship between osteonecrosis and LPS in a rat model of BRON-like lesions. Seventeen male rats were injected subcutaneously with zoledronic acid weekly for 4 weeks and divided into three groups: LPS (LPS administered into the bone marrow of...
Source: International Journal of Oral and Maxillofacial Surgery - November 22, 2014 Category: ENT & OMF Authors: O. Sakaguchi, S. Kokuryo, H. Tsurushima, J. Tanaka, M. Habu, M. Uehara, T. Nishihara, K. Tominaga Tags: Research Paper Source Type: research

Significance of Osteogenic Surface Coatings on Implants to Enhance Osseointegration Under Osteoporotic-like Conditions
Conclusion:Osteogenic coatings on implant surfaces enhanced osseointegration in animals with OP-like conditions. However, additional clinical studies are warranted to assess the role of osteogenic coatings in increasing osseointegration in patients with osteoporosis. (Source: Implant Dentistry)
Source: Implant Dentistry - November 21, 2014 Category: Dentistry Tags: Basic and Clinical Research Source Type: research

Effects of maternal bisphosphonate use on fetal and neonatal outcomes.
CONCLUSION: A limited body of published data suggests that maternal use of bisphosphonates before or during pregnancy does not have serious fetal or neonatal adverse effects. PMID: 25404594 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - November 20, 2014 Category: Drugs & Pharmacology Authors: Green SB, Pappas AL Tags: Am J Health Syst Pharm Source Type: research

Anti‐Sclerostin Antibody Treatment in a Rat Model of Progressive Renal Osteodystrophy
This article is protected by copyright. All rights reserved (Source: Journal of Bone and Mineral Research)
Source: Journal of Bone and Mineral Research - November 18, 2014 Category: Orthopaedics Authors: Sharon M. Moe, Neal X. Chen, Christopher L. Newman, Jason M. Organ, Michaela Kneissel, Ina Kramer, Vincent H. Gattone, Matthew R. Allen Tags: Original Article Source Type: research

The efficacy of bisphosphonates in preventing aromatase inhibitor induced bone loss for postmenopausal women with early breast cancer: a systematic review and meta-analysis.
Conclusion. Third generation bisphosphonates has an effect on BMD of patients who are on treatment of AIs in breast cancer. Furthermore, the patients treated with immediate ZOL had a significantly high risk of musculoskeletal ADR's than patients with delayed ZOL. PMID: 24795759 [PubMed] (Source: Journal of Oncology)
Source: Journal of Oncology - November 17, 2014 Category: Cancer & Oncology Tags: J Oncol Source Type: research

Selective efficacy of zoledronic acid on metastasis in a patient‐derived orthotopic xenograph (PDOX) nude‐mouse model of human pancreatic cancer
ConclusionsThe results of the present study indicate that ZA can selectively target metastasis in a pancreatic cancer PDOX model and that the combination of ZA and GEM should be evaluated clinically in the near future for this highly treatment‐resistant disease. J. Surg. Oncol. 2014;9999:XX–XX. © 2014 Wiley Periodicals, Inc. (Source: Journal of Surgical Oncology)
Source: Journal of Surgical Oncology - November 14, 2014 Category: Cancer & Oncology Authors: Yukihiko Hiroshima, Ali A. Maawy, Matthew H.G. Katz, Jason B. Fleming, Michael Bouvet, Itaru Endo, Robert M. Hoffman Tags: Research Article Source Type: research

Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions
K Hiroshima & M Tagawa (Source: Cell death and disease)
Source: Cell death and disease - November 13, 2014 Category: Internal Medicine Authors: S OkamotoY JiangK KawamuraM ShingyojiY TadaI SekineY TakiguchiK TatsumiH KobayashiH ShimadaK HiroshimaM Tagawa Source Type: research

Abstract C60: Snail transcription factor contributes to bone metastasis in prostate and breast cancer cells
Prostate cancer that is hormone refractory and has metastasized preferentially to bone is the main cause of prostate cancer death, especially in African American men. Receptor activator of nuclear factor kappa B ligand (RANKL) and its receptor (RANK) contributes to bone metastatic lesions and bisphosphonates such as Zometa and Fosamax have been used as antagonists of RANKL for the treatment of breast and prostate cancer metastasis. African American men have the highest bone mineral density compared to any other race, and the role this may play in prostate cancer metastasis to bone is not clear. A better understanding of bo...
Source: Cancer Epidemiology Biomarkers and Prevention - November 13, 2014 Category: Cancer & Oncology Authors: Smith, B. A., Henderson, V., Coke, C., Dumas, J., Hinton, C., Platt, M., Chung, L. K., Zayzafoon, M., Odero-Marah, V. A. Tags: Tumor Promotion and Progression: Poster Presentations - Proffered Abstracts Source Type: research

Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells
In this study, we tested the hypothesis, whether these agents regulate adhesion of breast cancer cells to extracellular matrix components. Treatment of breast cancer cells with zoledronic acid and atorvastatin, significantly impaired MDA-MB-231 breast cancer cell adhesion on the αvβ3 ligands gelatin and vitronectin, but had no effect on collagen type 1 (α2β1-ligand) and fibronectin (α5β1-ligand). Anti-adhesive effects of zoledronic acid were fully reversed by geranylgeranyl pyrophosphate (GGPP), but not by farnesylpyrophosphate (FPP). Furthermore, effects of zoledronic acid and atorvastatin...
Source: Journal of Bone Oncology - November 12, 2014 Category: Cancer & Oncology Source Type: research

The anti-tumour effects of zoledronic acid
Publication date: March 2014 Source:Journal of Bone Oncology, Volume 3, Issue 1 Author(s): Jamal Zekri , Maged Mansour , Syed Mustafa Karim Bone is the most common site for metastasis in patients with solid tumours. Bisphosphonates are an effective treatment for preventing skeletal related events and preserving quality of life in these patients. Zoledronic acid (ZA) is the most potent osteoclast inhibitor and is licensed for the treatment of bone metastases. Clodronate and pamidronate are also licensed for this indication. In addition, ZA has been demonstrated to exhibit antitumour effect. Direct and indirect mechanisms ...
Source: Journal of Bone Oncology - November 12, 2014 Category: Cancer & Oncology Source Type: research

Regulation of VEGF by mevalonate pathway inhibition in breast cancer
Publication date: September 2013 Source:Journal of Bone Oncology, Volume 2, Issue 3 Author(s): Tilman D. Rachner , Andy Göbel , Maria Junker , Josefa Hötzel , Peggy Benad-Mehner , Peyman Hadji , Lorenz C. Hofbauer Aminobisphosphonates are used for the treatment of benign and malignant bone disorders. As inhibitors of the mevalonate pathway they exert direct anti-tumor effects in vitro and in preclinical models of bone metastases. Bisphosphonates are thought to have an anti-angiogenic activity as decreased levels of VEGF have been reported in some, although not all patients, following treatment with bisphosphona...
Source: Journal of Bone Oncology - November 12, 2014 Category: Cancer & Oncology Source Type: research

A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer
Conclusions Studies comparing standard and de-escalated treatment with bone-targeted agents in breast cancer are rare. The benefits of standard treatment compared to de-escalated therapy on important clinical outcomes remain unclear. Future pragmatic studies must be conducted to determine the merits of this approach. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - November 12, 2014 Category: Cancer & Oncology Source Type: research

Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features—An exploratory analysis of placebo-controlled trials
Conclusion These exploratory analyses suggest a beneficial effect of ZOL on OS in patients with highly aggressive or advanced MBD. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - November 12, 2014 Category: Cancer & Oncology Source Type: research

Bone health in patients with prostate cancer
Conclusions The prevention and management of bone involvement in patients with prostate cancer are critical to quality of life in these patients and require an individualized approach. Before starting a prolonged androgen deprivation, baseline risk of fracture should be evaluated in order to adopt the proper protective measures. In patients with metastases, early treatments reducing the risk of bone events should be taken into account. (Source: Actas Urologicas Espanolas)
Source: Actas Urologicas Espanolas - November 11, 2014 Category: Urology & Nephrology Source Type: research

Effect of systemic administered zoledronic acid on osseointegration of a titanium implant in ovariectomized rats
Conclusions Systemic zoledronic acid improved tibial titanium implant osseointegration in an oestrogen-deficient rat model. (Source: Journal of Cranio Maxillofacial Surgery)
Source: Journal of Cranio Maxillofacial Surgery - November 10, 2014 Category: ENT & OMF Source Type: research

Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy
Abstract Summary Changes in bone mineral density (BMD) and trabecular bone score (TBS) were assessed in 70 patients who received either zoledronate (ZOL) (n = 34) or placebo (n = 36) for 2 years. In premenopausal women with breast cancer treatment-induced bone loss, 24 months of intravenous ZOL treatment significantly increased the lumbar spine BMD and the TBS. Introduction The aim of this study was to compare the effects of 4 mg intravenous zoledronate (ZOL) versus placebo (PLB), every 3 months, on the lum...
Source: Osteoporosis International - November 8, 2014 Category: Orthopaedics Source Type: research

The Effect of Bisphosphonates on Bone Mineral Density in Metastatic Prostate Cancer Patients Who Are Treated with Anti-Androgen Drugs and Radiotherapy
Objective: To evaluate the potential effect of bisphosphonates on bone mineral density (BMD) in patients who are treated with anti-androgen drugs and radiotherapy for metastatic prostate cancer. Materials and Methods: The data of 31 patients with metastatic prostate cancer who were treated with anti-androgen drugs and radiotherapy during a 1-year period were retrospectively reviewed. Patients were divided in 2 groups, in which 17 patients in group 1 were treated with zoledronic acid (4 mg/month, intravenous) and 14 patients in group 2 who did not receive zoledronic acid. BMD was measured before the treatment and at the end...
Source: Current Urology - November 7, 2014 Category: Urology & Nephrology Source Type: research

Role of periodontal disease in bisphosphonate‐related osteonecrosis of the jaws in ovariectomized rats
This study aimed to investigate the role of progressive periodontal disease in inducing bisphosphonate‐related osteonecrosis of the jaws (BRONJ) using an ovariectomized (OVX) rat model mimicking human intracortical remodeling process. Materials and methodsThirty 12‐week‐old Spraque–Dawly (SD) female rats were randomly assigned into two groups. All rats underwent bilateral ovariectomy. Six weeks after surgery, zoledronic acid (ZA) or vehicle control was administered intraperitoneally for 12 weeks. On the same day of injection, a cotton ligature was placed subgingivally around the first left lower molar to i...
Source: Clinical Oral Implants Research - November 5, 2014 Category: Dentistry Authors: Chun Lei Li, Weijia William Lu, Chaminda Jayampath Seneviratne, Wai Keung Leung, Roger A. Zwahlen, Li Wu Zheng Tags: Original Article Source Type: research

Unwrapping microcomputed tomographic images for measuring cortical osteolytic lesions in the 5T2 murine model of myeloma treated by bisphosphonate
Publication date: January 2015 Source:Micron, Volume 68 Author(s): Mambaye N’Diaye , Hélène Libouban , Eric Aguado , Béatrice Bouvard , Maurice Audran , Daniel Chappard Multiple myeloma is due to the proliferation of malignant plasma cells which increase the number of osteoclasts leading to trabecular and cortical bone osteolysis. The 5T2MM murine model reproduces the human disease and microcomputed tomography is a precise tool to investigate bone loss. Bisphosphonates (zoledronic acid or pamidronate) are used in preventing osteolysis. However, loss of cortical bone in not possible to quantify ...
Source: Micron - November 3, 2014 Category: Biology Source Type: research

Inhibition of PSCs by Bisphosphonates in PDAC
Pancreatic stellate cells (PSC) have been recognized as the principal cells responsible for the production of fibrosis in pancreatic ductal adenocarcinoma (PDAC). Recently, PSCs have been noted to share characteristics with cells of monocyte-macrophage lineage (MML cells). Thus, we tested whether PSCs could be targeted with the nitrogen-containing bisphosphonates (NBP; pamidronate or zoledronic acid), which are potent MML cell inhibitors. In addition, we tested NBPs treatment combination with nanoparticle albumin–bound paclitaxel (nab-paclitaxel) to enhance antitumor activity. In vitro, we observed that PSCs possess ...
Source: Molecular Cancer Therapeutics - November 3, 2014 Category: Cancer & Oncology Authors: Gonzalez-Villasana, V., Rodriguez-Aguayo, C., Arumugam, T., Cruz-Monserrate, Z., Fuentes-Mattei, E., Deng, D., Hwang, R. F., Wang, H., Ivan, C., Garza, R. J., Cohen, E., Gao, H., Armaiz-Pena, G. N., del C. Monroig-Bosque, P., Philip, B., Rashed, M. H., As Tags: Small Molecule Therapeutics Source Type: research

Zoledronic acid exerts antitumor effects in NB4 acute promyelocytic leukemia cells by inducing apoptosis and S phase arrest
Publication date: Available online 19 September 2014 Source:Biomedicine & Pharmacotherapy Author(s): Shou-Sheng Liu , Xiao-Pai Wang , Xiu-Bo Li , Jia-Yi Liang , Ling-Ling Liu , Ying Lu , Xue-Yun Zhong , Yun-Xian Chen The aim of this study was to investigate the antitumor effect of zoledronic acid (ZOL) in the NB4 human acute promyelocytic leukemia (APL) cell line and explore the potential mechanism of action of this compound. NB4 cells were exposed to various concentrations (0–200μM) of ZOL. Cell viability was measured by MTS assay. The extent of cell apoptosis and distribution of cells in the different ...
Source: Biomedicine and Pharmacotherapy - November 1, 2014 Category: Drugs & Pharmacology Source Type: research

Impact on Hospitalization Derived from the Use of Denosumab for the Prevention of Skeletal-Related Events in Patients with Bone Metastases Secondary to Breast Cancer in Germany
Skeletal-related events (SREs) defined as pathologic fracture, radiation to bone, surgery to bone and spinal cord compression, are common consequences of bone metastasis. Prior studies have shown that SREs increase the utilization of health care resources, including hospitalizations. We estimated the decrease in hospitalizations when a novel superior therapy is used (denosumab), in substitution of zoledronic acid (zol), to treat patients with bone metastases secondary to breast cancer in Germany. (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: I. Diel, R. Ikenberg, J. Cristino, F. Gatta, Y. Qian, J. Arellano Source Type: research

Cost-Effectiveness of denosumab vs. Brand or generic zoledronic acid in patients with prostate cancer in kazakhstan
A phase III clinical trial demonstrated the advantage of denosumab over zoledronic acid(ZA) in delaying the first on-study and subsequent skeletal-related events(SREs) in patients with prostate cancer(PC). Recently, generic ZA became available. The purpose of this study was to examine the cost-effectiveness of denosumab vs. brand or generic ZA in the prevention of SREs in Kazakhstani patients with PC. (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: C. Bektur, T. Nurgozhin Source Type: research

Cost-Effectiveness of Denosumab vs. Brand or Generic zoledronic Acid in Patients with Breast Cancer in Kazakhstan
Denosumab is recomended for preventing skeletal-related events (SREs) in adults with bone metastases from breast cancer (BC). Since recently generic zoledronic acid (ZA) became available, the aim of present study was to access the cost-effectiveness of denosumab vs. brand or generic ZA in the prevention of SREs in Kazakhstani patients with BC. (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: C. Bektur, T. Nurgozhin Source Type: research

Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials
Abstract Bisphosphonates are potent inhibitors of bone resorption, widely used for the management of osteoporosis and fracture prevention. Recent evidence suggests that bisphosphonates may have beneficial effects in the treatment of thalassemia-associated osteoporosis, a complex and multifactorial condition. Here we summarise available data about the efficacy and tolerability of bisphosphonates in beta-thalassemic patients. Randomised controlled trials (RCTs) of bisphosphonates in beta-thalassemia were identified searching PubMed. Studies were reviewed to retrieve relevant clinical information. The following vari...
Source: Journal of Bone and Mineral Metabolism - November 1, 2014 Category: Orthopaedics Source Type: research

Amplified lipid rafts of malignant cells constitute a target for inhibition of aberrantly active NFAT and melanoma tumor growth by the aminobisphosphonate zoledronic acid
Nuclear factors of activated T cells (NFAT) are critical modulators of cancer cell growth and survival. However, the mechanisms of their oncogenic dysregulation and strategies for targeting in tumors remain elusive. Here, we report coupling of anti- apoptotic NFAT (NFAT2) activation to cholesterol-enriched lipid raft microdomains of malignant melanoma cells and interruption of this pathway by the aminobisphosphonate zoledronic acid (Zol). The pathway was indicated by capability of Zol to promote apoptosis and to retard in vivo outgrowth of tumorigenic melanoma cell variants through inhibition of permanently active NFAT2. N...
Source: Carcinogenesis - October 31, 2014 Category: Cancer & Oncology Authors: Levin-Gromiko, U., Koshelev, V., Kushnir, P., Fedida-Metula, S., Voronov, E., Fishman, D. Tags: Original Manuscript Source Type: research

Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis
This study evaluated the baseline patient characteristics associated with the time to biochemical progression and overall survival in patients who participated in a phase II trial on zoledronic acid combined with the initial androgen-deprivation therapy for treatment-naïve bone-metastatic prostate cancer. Methods Patients received zoledronic acid 4 mg intravenously every 4 weeks for up to 24 months, concomitantly started with bicalutamide 80 mg orally every day and goserelin acetate 10.8 mg subcutaneously every 12 weeks. ...
Source: World Journal of Urology - October 30, 2014 Category: Urology & Nephrology Source Type: research

Nitric oxide-mediated cytotoxic effect induced by zoledronic acid treatment on human gingival fibroblasts
Conclusions Our results suggest ROS involvement in NO overproduction, due to nNOS recruitment, both at low and high doses. In turn, NO release seems to be able to trigger the inflammatory response only when high doses are administered, thus confirming the ZA cytotoxic effect on HGFs. Clinical relevance The knowledge of ZA-mediated cytotoxicity mechanisms on HGFs allows to better understand drug pharmacological activity. (Source: Clinical Oral Investigations)
Source: Clinical Oral Investigations - October 29, 2014 Category: Dentistry Source Type: research

Anabolic and Antiresorptive Therapy for Osteoporosis: Combination and Sequential Approaches
Abstract In the recent Bone Key Reports review, it was noted that combinations of anabolic and antiresorptive agents have potential to improve bone density and bone strength more than either agent as monotherapy. Small clinical trials have been performed evaluating combinations of PTH1-34 (TPTD) or PTH1-84 (PTH) with a variety of antiresorptives including hormone/estrogen therapy, raloxifene, alendronate, risedronate, ibandronate, zoledronic acid, and denosumab. Most of the studies evaluate dual-energy X-ray absorptiometry outcomes, and a few trials report volumetric mineral density (BMD) by quantitative computed ...
Source: Current Osteoporosis Reports - October 23, 2014 Category: Orthopaedics Source Type: research

Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report
This critical case describes a 73 year-old female, recently diagnosed with multiple myeloma and prescribed zolendronic acid, presenting with fever, vomiting and hypocalcemia. Treatment efforts led to severe hypocalcaemia, to which a later identified Vitamin D deficiency was associated with. (Source: BioMed Central)
Source: BioMed Central - October 23, 2014 Category: Journals (General) Authors: Adrian P AldaveShikha Jaiswal Source Type: research

P3-5-3 * changes of n-telopeptide crosslinked type 1 collagen in breast cancer patients with bone metastasis receiving denosumab
Conclusion: This data clarifies the changes of u-NTx in breast cancer patients with BM receiving denosumab. u-NTx measurement may be useful for monitoring the effectiveness of denosumab preventing SREs. (Source: Annals of Oncology)
Source: Annals of Oncology - October 19, 2014 Category: Cancer & Oncology Authors: Mizuno, Y., Kurata, N., Mori, T., Miyauchi, M. Tags: Poster Session (Poster presentations categorized by each organ) Source Type: research

Biology and management of myeloma-related bone disease
Publication date: April–June 2014 Source:Acta Haematologica Polonica, Volume 45, Issue 2 Author(s): Evangelos Terpos , Nikolaos Kanellias , Krzysztof Giannopoulos Bone disease is one of the most common complications of multiple myeloma. It is the result of increased osteoclast activity which is not compensated by osteoblast activity and leads to osteolytic lesions characterized by bone pain and increased risk for pathological fracture, spinal cord compression and need for radiotherapy or surgery to the bone. Recent studies have revealed novel pathways and molecules that are involved in the biology of myeloma bone d...
Source: Acta Haematologica Polonica - October 12, 2014 Category: Hematology Source Type: research

Current and future treatments of osteoporosis in men
Publication date: Available online 16 September 2014 Source:Best Practice & Research Clinical Endocrinology & Metabolism Author(s): Jean-Marc Kaufman , Bruno Lapauw , Stefan Goemaere One in three osteoporotic fractures occur in men and the consequences of a fracture in men tend to be more severe than in women. Still, only a small minority of men with high risk of fracture are detected and treated. Although there are gender differences in the pathophysiology of osteoporosis, such as in the pattern of bone loss, similarities predominate, which is also the case for clinical risk factors. It seems appropriate...
Source: Best Practice and Research Clinical Endocrinology and Metabolism - October 12, 2014 Category: Endocrinology Source Type: research

Effects of zoledronic acid on osteoblasts in three-dimensional culture
Conclusion ZA sensitivity of osteoblasts depends on concentration and experimental models. The dual dose-dependent effects of ZA on osteoblasts cultured as spheroids, thereby promoting or inhibiting cell proliferation, may provide opportunities in tissue engineering. At last, the hFOB spheroid culture system represents a valuable model for the exploration of the molecular basis of BPs action on osteoblasts and for the development and evaluation of implantable biomaterials in bone sites. (Source: Journal of Dental Sciences)
Source: Journal of Dental Sciences - October 12, 2014 Category: Dentistry Source Type: research

Epidemiology, pharmacology and clinical characterization of bisphosphonate-related osteonecrosis of the jaw. A retrospective study of 70 cases.
CONCLUSIONS: 25% of the BRONJ cases were related to the administration of oral bisphosphonates, especially alendronate. Zoledronic acid was the bisphosphonate that required the fewest milligrams to induce osteonecrosis. Single bone exposure was the most common clinical finding, especially in the molar mandibular region in patients with metastatic disease. PMID: 25308796 [PubMed - as supplied by publisher] (Source: Acta Otorrinolaringologica Espanola)
Source: Acta Otorrinolaringologica Espanola - October 9, 2014 Category: ENT & OMF Authors: Pelaz A, Junquera L, Gallego L, García-Consuegra L, García-Martínez L, Cutilli T, Olay S Tags: Acta Otorrinolaringol Esp Source Type: research

Pathologic fracture in patients with metastatic prostate cancer
Purpose of review: This review will describe the management of patients with prostate cancer and bone metastases with a particular emphasis on recent advances in this area. Recent findings: Two osteoclast-targeted agents have been shown to decrease the incidence of skeletal-related events in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases. These agents are the bisphosphonate zoledronic acid and the monoclonal antibody denosumab. Recent advances in the field include the approval of several agents shown to extend survival in mCRPC. Among these agents, the androgen-pathway inhibitors,...
Source: Current Opinion in Urology - October 2, 2014 Category: Urology & Nephrology Tags: BONE HEALTH IN UROLOGIC PATIENTS: Edited by Benjamin K. Canales Source Type: research

Severe visual loss secondary to retinal toxicity after intravenous use of bisphosphonate in an eye with known chloroquine maculopathy
Conclusion:Exposure to zoledronic acid seems to have precipitated acute visual loss in an eye with known chloroquine toxicity after 15 years of quiescence. Retinal toxicity may represent a rare adverse reaction to zoledronic acid, but this case suggests that caution should be used when administering this medication to patients with compromised retinal integrity. (Source: Retinal Cases and Brief Reports)
Source: Retinal Cases and Brief Reports - October 1, 2014 Category: Opthalmology Tags: Case Report Source Type: research